Top Page
Singular Health Group Ltd
(Sydney:SHG)
Singular Health Group Ltd (SHG) vs. iShares MSCI Australia ETF (EWA)
Singular Health Group Ltd Business Overview & Revenue Model
Singular Health Group Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 961.53K | 557.61K | 934.07K | 28.12K | 54.03K | 193.64K |
| Gross Profit | -2.01M | -86.22K | 516.36K | -3.58M | -2.11M | -1.62M |
| EBITDA | -8.14M | -6.27M | -2.58M | -4.52M | -5.65M | -2.86M |
| Net Income | -7.43M | -6.38M | -4.92M | -5.39M | -5.99M | -4.46M |
Balance Sheet | ||||||
| Total Assets | 12.55M | 14.21M | 2.35M | 3.00M | 2.14M | 5.43M |
| Cash, Cash Equivalents and Short-Term Investments | 11.06M | 13.68M | 1.45M | 691.51K | 1.14M | 4.14M |
| Total Debt | 113.71K | 0.00 | 218.45K | 2.51M | 85.66K | 147.59K |
| Total Liabilities | 856.60K | 1.11M | 909.59K | 2.94M | 391.50K | 345.10K |
| Stockholders Equity | 11.69M | 13.10M | 1.44M | 61.89K | 1.75M | 5.08M |
Cash Flow | ||||||
| Free Cash Flow | -4.38M | -2.37M | -2.51M | -2.49M | -2.92M | -2.22M |
| Operating Cash Flow | -4.23M | -2.34M | -2.44M | -2.46M | -2.91M | -1.91M |
| Investing Cash Flow | -8.49M | 88.14K | -3.56K | -635.21K | -17.12K | -610.57K |
| Financing Cash Flow | 6.36M | 14.48M | 3.21M | 2.65M | -69.25K | 6.52M |
Singular Health Group Ltd Technical Analysis
Singular Health Group Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$131.61M | 26.51 | 1.89% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$76.38M | -6.28 | -12.35% | ― | 15.99% | 22.05% | |
45 Neutral | AU$35.53M | -3.13 | -8647.54% | ― | 25.98% | 22.10% | |
44 Neutral | AU$45.05M | -5.70 | -13.83% | ― | 3.61% | -17.03% | |
43 Neutral | AU$80.50M | -6.64 | ― | ― | ― | ― |
Singular Health Group Ltd Corporate Events
Singular Health Group reported a quarter of strong operational progress, highlighted by the continued rollout of its Provider Network Solution (PNS) contract in the U.S., where deployment of an additional 500 3DICOM MD licences is underway and triggering a further US$500,000 payment, with early results indicating duplicate imaging reductions exceeding targets in a US$16.5 billion addressable market. The company advanced its Life Radiology pilot in Miami into full patient deployment, replacing CD-ROMs with cloud-based access via 3DICOM Patient using its MFTP protocol, while also pursuing major U.S. growth opportunities including a multi‑million‑dollar project request to the U.S. House of Representatives for a Florida Medicaid imaging repository, a separate MOU with Florida International University, and securing key regulatory milestones such as FDA 510(k) clearance for 3DICOM MD Cloud and ISO 13485 renewal, all supported by a cash runway of around eight quarters.
The most recent analyst rating on (AU:SHG) stock is a Hold with a A$0.24 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Limited has raised $344,000 through the exercise of 1,720,000 unlisted options at $0.20 each, resulting in the issuance of an equivalent number of fully paid ordinary shares. The newly issued shares will be subject to a 12‑month voluntary escrow period, and the company has confirmed compliance with relevant Corporations Act disclosure and reporting obligations, signalling a modest capital injection while maintaining regulatory transparency for shareholders.
The most recent analyst rating on (AU:SHG) stock is a Hold with a A$0.24 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has applied to the ASX for quotation of 1,720,000 new fully paid ordinary shares, issued on 19 January 2026, following the exercise of options or conversion of other securities. The additional share quotation modestly expands the company’s equity base, potentially improving liquidity in its stock and reflecting ongoing utilisation of its capital management and incentive structures, with implications for existing shareholders through incremental dilution but also signalling continued investor or holder engagement with the company’s securities.
The most recent analyst rating on (AU:SHG) stock is a Hold with a A$0.24 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group has secured U.S. FDA 510(k) clearance for 3DICOM MD Cloud, a Class II Software as a Medical Device and cloud-based evolution of its previously cleared 3DICOM MD desktop software, allowing the company to market and deploy the platform clinically across the United States. The accelerated 40-day review, well ahead of the typical timeline, underscores the robustness of the submission and enables the company to advance its U.S. commercial strategy with a browser-based solution that removes hardware and complex IT installation requirements. By adding support for X-ray and ultrasound alongside CT, MRI and PET, the cloud platform significantly broadens the range of clinical pathways it can serve and positions Singular Health to address an estimated US$16.5 billion U.S. market opportunity in reducing duplicate imaging, potentially enhancing adoption among large healthcare organisations and strengthening its competitive position in medical imaging software.
The most recent analyst rating on (AU:SHG) stock is a Hold with a A$0.24 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has announced the cessation of 5,000,000 listed options (ASX code SHGAY) that expired unexercised on 23 December 2025, each carrying an exercise price of A$0.40. The lapse of these options slightly simplifies the company’s capital structure by removing a class of potential dilutive securities, which may alter future capital-raising flexibility but has no immediate cash impact, and signals that current market conditions did not support conversion at the exercise price.
The most recent analyst rating on (AU:SHG) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has notified the ASX that a tranche of listed options has lapsed, reducing its pool of potential dilutive securities. The company confirmed that 2,030,000 options exercisable at A$0.30 and expiring on 20 December 2025 ceased to exist unexercised, a routine capital management event that slightly streamlines its issued capital structure and may marginally lessen prospective dilution for existing shareholders.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Limited has disclosed a change in director Denning Chong’s relevant interests in the company’s securities, involving a mix of direct and indirect holdings across ordinary shares, unlisted options, and performance rights held through several controlled entities. As part of his managing director remuneration package and following shareholder approval at the company’s 2025 annual general meeting, Chong has been granted 6 million new unlisted incentive options exercisable at $0.55 and expiring on 30 November 2029, which are subject to various vesting conditions; the award increases his potential equity exposure and further aligns executive incentives with long-term shareholder outcomes.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd, listed on the ASX under the code SHG, has notified the market of a new issuance of unquoted equity securities in the form of options. The company has issued 6 million unlisted options, each with an exercise price of $0.55 and an expiry date of 30 November 2029, dated 18 December 2025, signalling a move to potentially raise additional capital in the future and further align incentives for stakeholders through long-dated option-based compensation or financing structures.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd announced the issuance of 900,000 fully paid ordinary shares following the exercise of unlisted options, raising $135,000. This move reflects the company’s ongoing efforts to strengthen its financial position and support its mission of advancing medical technology solutions. The announcement, authorized by the Board of Directors, indicates compliance with relevant provisions of the Corporations Act, ensuring transparency and adherence to regulatory standards.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.
Singular Health Group Ltd has announced the quotation of 900,000 fully paid ordinary securities on the Australian Securities Exchange (ASX). This move, resulting from the exercise of options or conversion of other securities, is part of the company’s ongoing efforts to enhance its market presence and operational capacity.
The most recent analyst rating on (AU:SHG) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Singular Health Group Ltd stock, see the AU:SHG Stock Forecast page.